ASGCT–OTXL joint venture platform goes live with demo at ASGCT 2026 Annual Meeting and applications opening this month for qualified Asset listings BOSTON, May 14, 2026 /PRNewswire/ -- The American ...
Data highlight advancements across ElevateBio's targeted gene insertion platform, powered by retrotransposon and machine learning-optimized ...
Imviva’s ASGCT presentation highlights encouraging clinical responses in SLE. Among 18 evaluable patients with SLE/lupus nephritis (LN) treated with CTA313, with a median follow-up of six months: 50% ...
Oral presentation describes machine learning-guided multiparameter optimization of lipid nanoparticles (LNPs) to achieve selective delivery to adipose tissue Two poster presentations highlight Mirai’s ...
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 ...
Terry Flotte, MD, steps down as ASGCT president at the end of this week. In this exclusive interview, Terry shares the ...
The American Society of Gene & Cell Therapy's 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of ...
Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on ...
Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...
Data demonstrate dose‑dependent hearing rescue across multiple mouse modelsCAMBRIDGE, Mass.--(BUSINESS ...
Platform data establish Modified DNA’s potential to overcome two of the barriers that have kept DNA from becoming a practical ...
Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results